NYSE:BIO

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Bio-Rad Laboratories, Inc. develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the United States, Canada, and Latin America. More Details


Snowflake Analysis

Flawless balance sheet with solid track record.


Similar Companies

Share Price & News

How has Bio-Rad Laboratories's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BIO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: BIO's weekly volatility (6%) has been stable over the past year.


Market Performance


7 Day Return

-12.8%

BIO

-4.1%

US Life Sciences

1.8%

US Market


1 Year Return

39.1%

BIO

33.9%

US Life Sciences

20.4%

US Market

Return vs Industry: BIO exceeded the US Life Sciences industry which returned 33.9% over the past year.

Return vs Market: BIO exceeded the US Market which returned 20.4% over the past year.


Shareholder returns

BIOIndustryMarket
7 Day-12.8%-4.1%1.8%
30 Day-11.2%-2.4%6.0%
90 Day0.7%5.3%6.8%
1 Year39.1%39.1%34.2%33.9%23.2%20.4%
3 Year96.2%96.2%91.5%90.2%47.4%37.6%
5 Year268.9%268.9%167.8%164.3%91.9%70.8%

Long-Term Price Volatility Vs. Market

How volatile is Bio-Rad Laboratories's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Bio-Rad Laboratories undervalued compared to its fair value and its price relative to the market?

4.37x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: BIO ($516.56) is trading above our estimate of fair value ($222.1)

Significantly Below Fair Value: BIO is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: BIO is good value based on its PE Ratio (4.4x) compared to the US Life Sciences industry average (41.8x).

PE vs Market: BIO is good value based on its PE Ratio (4.4x) compared to the US market (19.7x).


Price to Earnings Growth Ratio

PEG Ratio: BIO's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: BIO is good value based on its PB Ratio (1.7x) compared to the US Life Sciences industry average (6.5x).


Next Steps

Future Growth

How is Bio-Rad Laboratories forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

-111.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BIO's earnings are forecast to decline over the next 3 years (-111.3% per year).

Earnings vs Market: BIO's earnings are forecast to decline over the next 3 years (-111.3% per year).

High Growth Earnings: BIO's earnings are forecast to decline over the next 3 years.

Revenue vs Market: BIO's revenue (3.9% per year) is forecast to grow slower than the US market (10.2% per year).

High Growth Revenue: BIO's revenue (3.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BIO's Return on Equity is forecast to be low in 3 years time (4.5%).


Next Steps

Past Performance

How has Bio-Rad Laboratories performed over the past 5 years?

64.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BIO has a high level of non-cash earnings.

Growing Profit Margin: BIO's current net profit margins are higher than last year (17%).


Past Earnings Growth Analysis

Earnings Trend: BIO's earnings have grown significantly by 64% per year over the past 5 years.

Accelerating Growth: BIO's earnings growth over the past year (798.9%) exceeds its 5-year average (64% per year).

Earnings vs Industry: BIO earnings growth over the past year (798.9%) exceeded the Life Sciences industry 30.4%.


Return on Equity

High ROE: BIO's Return on Equity (39.9%) is considered high.


Next Steps

Financial Health

How is Bio-Rad Laboratories's financial position?


Financial Position Analysis

Short Term Liabilities: BIO's short term assets ($2.3B) exceed its short term liabilities ($986.7M).

Long Term Liabilities: BIO's short term assets ($2.3B) exceed its long term liabilities ($2.2B).


Debt to Equity History and Analysis

Debt Level: BIO's debt to equity ratio (4.8%) is considered satisfactory.

Reducing Debt: BIO's debt to equity ratio has reduced from 17.4% to 4.8% over the past 5 years.

Debt Coverage: BIO's debt is well covered by operating cash flow (105.4%).

Interest Coverage: BIO's interest payments on its debt are well covered by EBIT (58.6x coverage).


Balance Sheet


Next Steps

Dividend

What is Bio-Rad Laboratories's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BIO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BIO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BIO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.2yrs

Average management tenure


CEO

Norman Schwartz (70 yo)

17.83yrs

Tenure

US$7,261,053

Compensation

Mr. Norman D. Schwartz has been the Chief Executive Officer and President of Bio-Rad Laboratories, Inc. since January 1, 2003 and has been its Chairman since 2012. Mr. Schwartz served as Vice President of ...


CEO Compensation Analysis

Compensation vs Market: Norman's total compensation ($USD7.26M) is below average for companies of similar size in the US market ($USD10.82M).

Compensation vs Earnings: Norman's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Norman Schwartz
Chairman17.83yrsUS$7.26m3.79%
$ 585.7m
Ilan Daskal
Executive VP & CFO1.58yrsUS$2.14m0.0015%
$ 236.2k
Andrew Last
Executive VP & COO1.58yrsUS$2.73m0.0023%
$ 352.0k
Michael Crowley
Executive Vice President of Global Commercial Operations5.92yrsUS$1.83m0.014%
$ 2.1m
Annette Tumolo
Executive VP & President of Life Science Group3.17yrsUS$1.93m0.012%
$ 1.9m
Ajit Ramalingam
Senior VP & Chief Accounting Officer0.58yrno datano data
Diane Dahowski
Senior Vice President of Global Technology & Systemsno datano datano data
Timothy Ernst
Executive VP4.42yrsno data0.0058%
$ 892.3k
Colleen Corey
Senior Vice President of Global Human Resourcesno datano datano data
Lee Boyd
Senior Vice President of Global Commercial Operations - Asia Pacificno datano datano data
John Bussell
Senior Vice President of Global Operations of Clinical Diagnostics Groupno datano datano data
Scott Jenest
Executive Vice President of Global Supply Chainno datano datano data

3.2yrs

Average Tenure

60yo

Average Age

Experienced Management: BIO's management team is considered experienced (3.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Norman Schwartz
Chairman17.83yrsUS$7.26m3.79%
$ 585.7m
Gregory Hinckley
Lead Independent Director3.58yrsUS$150.00k0.0017%
$ 259.3k
Alice Schwartz
Director53.83yrsUS$120.00k10.8%
$ 1.7b
Jeffrey Edwards
Independent Director3.58yrsUS$140.00kno data
Arnold Pinkston
Independent Director3.58yrsUS$130.00kno data
Melinda Pei
Independent Director3.83yrsUS$143.00kno data

3.7yrs

Average Tenure

66yo

Average Age

Experienced Board: BIO's board of directors are considered experienced (3.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Bio-Rad Laboratories, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Bio-Rad Laboratories, Inc.
  • Ticker: BIO
  • Exchange: NYSE
  • Founded: 1952
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$15.437b
  • Shares outstanding: 29.83m
  • Website: https://www.bio-rad.com

Number of Employees


Location

  • Bio-Rad Laboratories, Inc.
  • 1000 Alfred Nobel Drive
  • Hercules
  • California
  • 94547
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BIO.BNYSE (New York Stock Exchange)Class B Common StockUSUSDOct 1974
BIONYSE (New York Stock Exchange)YesClass A Common StockUSUSDFeb 1980
BUWADB (Deutsche Boerse AG)YesClass A Common StockDEEURFeb 1980

Biography

Bio-Rad Laboratories, Inc. develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the United States, Canada, and Latin America. ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/24 23:59
End of Day Share Price2020/11/24 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.